Literature DB >> 19801385

Improved insulin sensitivity by calorie restriction is associated with reduction of ERK and p70S6K activities in the liver of obese Zucker rats.

Yanbin Zheng1, Wenshuo Zhang, Elisha Pendleton, Sanhua Leng, Jiong Wu, Ridong Chen, Xiao Jian Sun.   

Abstract

Calorie restriction (CR) improves obesity-related insulin resistance through undefined molecular mechanisms. Insulin receptor substrate (IRS)-1 serine/threonine kinases have been proposed to modulate insulin sensitivity through phosphorylation of IRS proteins. The aim of this study is to test the hypothesis that changes in the activity of IRS1 serine/threonine kinases may underlie the molecular mechanism of CR in improving insulin sensitivity. Obese and lean Zucker rats were subjected to 40% CR or allowed to feed ad libitum (AL) for 20 weeks; body weight and insulin sensitivity were monitored throughout this period. The activity of IRS1 serine/threonine kinases - including JNK, ERK, MTOR/p70(S6K) (RPS6KB1 as listed in the MGI Database), glycogen synthase kinase 3beta (GSK3B), AMPK (PRKAA1 as listed in the MGI Database), and protein kinase C (PRKCQ) in liver tissue extracts was measured by an in vitro kinase assay using various glutathione-S-transferase (GST)-IRS1 fragments as substrates, while phosphorylation of IRS1 and serine kinases was determined by western blotting using phosphospecific antibodies. CR in obese rats significantly reduced body weight and increased insulin sensitivity compared to AL controls. Serine kinase activity toward IRS1(S612) (corresponding to S616 in human IRS1) and IRS1(S632/635) (corresponding to S636/639 in human IRS1) was increased in obese rats compared to lean littermates, and was markedly decreased following CR. Concomitantly, obesity increased and CR decreased the activity of hepatic ERK and p70(S6K) against IRS1. The close association between the activity of hepatic ERK and p70(S6K) with insulin resistance suggests an important role for ERK and p70(S6K) in the development of insulin resistance, presumably via phosphorylation of IRS proteins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19801385      PMCID: PMC3050029          DOI: 10.1677/JOE-09-0181

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  48 in total

Review 1.  Uncoupling insulin signalling by serine/threonine phosphorylation: a molecular basis for insulin resistance.

Authors:  Y Zick
Journal:  Biochem Soc Trans       Date:  2004-11       Impact factor: 5.407

2.  Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes.

Authors:  S E Nikoulina; T P Ciaraldi; S Mudaliar; P Mohideen; L Carter; R R Henry
Journal:  Diabetes       Date:  2000-02       Impact factor: 9.461

3.  Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302.

Authors:  Eric D Werner; Jongsoon Lee; Lone Hansen; Minsheng Yuan; Steven E Shoelson
Journal:  J Biol Chem       Date:  2004-06-14       Impact factor: 5.157

Review 4.  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.

Authors:  Diane C Fingar; John Blenis
Journal:  Oncogene       Date:  2004-04-19       Impact factor: 9.867

5.  Insulin and obesity in the Zucker genetically obese rat "fatty".

Authors:  L M Zucker; H N Antoniades
Journal:  Endocrinology       Date:  1972-05       Impact factor: 4.736

6.  Glucose-induced insulin resistance of skeletal-muscle glucose transport and uptake.

Authors:  E A Richter; B F Hansen; S A Hansen
Journal:  Biochem J       Date:  1988-06-15       Impact factor: 3.857

7.  Comparison of the enteroinsular axis in two strains of obese rat, the fatty Zucker and the JCR:LA-corpulent.

Authors:  R A Pederson; R V Campos; A M Buchan; C B Chisholm; J C Russell; J C Brown
Journal:  Int J Obes       Date:  1991-07

8.  Protein kinase C Theta inhibits insulin signaling by phosphorylating IRS1 at Ser(1101).

Authors:  Yu Li; Timothy J Soos; Xinghai Li; Jiong Wu; Matthew Degennaro; Xiaojian Sun; Dan R Littman; Morris J Birnbaum; Roberto D Polakiewicz
Journal:  J Biol Chem       Date:  2004-09-10       Impact factor: 5.157

9.  Nutrient-dependent and insulin-stimulated phosphorylation of insulin receptor substrate-1 on serine 302 correlates with increased insulin signaling.

Authors:  Jodel Giraud; Rebecca Leshan; Yong-Hee Lee; Morris F White
Journal:  J Biol Chem       Date:  2003-11-17       Impact factor: 5.157

10.  The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins.

Authors:  Laura S Harrington; Greg M Findlay; Alex Gray; Tatiana Tolkacheva; Simon Wigfield; Heike Rebholz; Jill Barnett; Nick R Leslie; Susan Cheng; Peter R Shepherd; Ivan Gout; C Peter Downes; Richard F Lamb
Journal:  J Cell Biol       Date:  2004-07-12       Impact factor: 10.539

View more
  26 in total

Review 1.  Age-related cardiovascular disease and the beneficial effects of calorie restriction.

Authors:  Miranda M Y Sung; Jason R B Dyck
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

Review 2.  Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities.

Authors:  Lakshmi Pulakat; Vincent G DeMarco; Sivakumar Ardhanari; Anand Chockalingam; Rukhsana Gul; Adam Whaley-Connell; James R Sowers
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-03       Impact factor: 3.619

3.  Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.

Authors:  Ezra E W Cohen; Kehua Wu; Christine Hartford; Masha Kocherginsky; Kimberly Napoli Eaton; Yuanyuan Zha; Anitha Nallari; Michael L Maitland; Kammi Fox-Kay; Kristin Moshier; Larry House; Jacqueline Ramirez; Samir D Undevia; Gini F Fleming; Thomas F Gajewski; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2012-08-07       Impact factor: 12.531

4.  Hyperglycemia- and hyperinsulinemia-induced insulin resistance causes alterations in cellular bioenergetics and activation of inflammatory signaling in lymphatic muscle.

Authors:  Yang Lee; James D Fluckey; Sanjukta Chakraborty; Mariappan Muthuchamy
Journal:  FASEB J       Date:  2017-03-15       Impact factor: 5.191

5.  Saturated fatty acids activate ERK signaling to downregulate hepatic sortilin 1 in obese and diabetic mice.

Authors:  Lipeng Bi; John Y L Chiang; Wen-Xing Ding; Winston Dunn; Benjamin Roberts; Tiangang Li
Journal:  J Lipid Res       Date:  2013-07-31       Impact factor: 5.922

6.  Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity.

Authors:  Dudley W Lamming; Lan Ye; Pekka Katajisto; Marcus D Goncalves; Maki Saitoh; Deanna M Stevens; James G Davis; Adam B Salmon; Arlan Richardson; Rexford S Ahima; David A Guertin; David M Sabatini; Joseph A Baur
Journal:  Science       Date:  2012-03-30       Impact factor: 47.728

7.  Hepatic mTORC1 Opposes Impaired Insulin Action to Control Mitochondrial Metabolism in Obesity.

Authors:  Blanka Kucejova; Joao Duarte; Santhosh Satapati; Xiaorong Fu; Olga Ilkayeva; Christopher B Newgard; James Brugarolas; Shawn C Burgess
Journal:  Cell Rep       Date:  2016-06-23       Impact factor: 9.423

8.  Inhibitory cross-talk between the AMPK and ERK pathways mediates endoplasmic reticulum stress-induced insulin resistance in skeletal muscle.

Authors:  Seung-Lark Hwang; Yong-Tae Jeong; Xian Li; Yong Deuk Kim; Yue Lu; Young-Chae Chang; In-Kyu Lee; Hyeun Wook Chang
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

9.  Hepatic ERK activity plays a role in energy metabolism.

Authors:  Ping Jiao; Bin Feng; Yujie Li; Qin He; Haiyan Xu
Journal:  Mol Cell Endocrinol       Date:  2013-05-31       Impact factor: 4.102

10.  Insulin activates RSK (p90 ribosomal S6 kinase) to trigger a new negative feedback loop that regulates insulin signaling for glucose metabolism.

Authors:  Nicolas Smadja-Lamère; Michael Shum; Paul Déléris; Philippe P Roux; Jun-Ichi Abe; André Marette
Journal:  J Biol Chem       Date:  2013-09-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.